



Physical activity assessed in routine care predicts mortality after a COPD hospitalisation

Marilyn L. Moy¹, Michael K. Gould², In-Lu Amy Liu², Janet S. Lee² and
Huong Q. Nguyen²

Affiliations: ¹VA Boston Healthcare System, Pulmonary and Critical Care Section, Harvard Medical School, Boston, MA, USA. ²Dept of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Correspondence: Huong Q. Nguyen, Dept of Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Avenue, 2nd Floor, Pasadena, CA 91101, USA. E-mail: huong.q.nguyen@kp.org

ABSTRACT The independent relationship between physical inactivity and risk of death after an index chronic obstructive pulmonary disease (COPD) hospitalisation is unknown.

We conducted a retrospective cohort study in a large integrated healthcare system. Patients were included if they were hospitalised for COPD between January 1, 2011 and December 31, 2011. All-cause mortality in the 12 months after discharge was the primary outcome. Physical activity, expressed as self-reported minutes of moderate to vigorous physical activity (MVPA), was routinely assessed at outpatient visits prior to hospitalisation. 1727 (73%) patients were inactive (0 min of MVPA per week), 412 (17%) were insufficiently active (1–149 min of MVPA per week) and 231 (10%) were active (≥ 150 min of MVPA per week). Adjusted Cox regression models assessed risk of death across the MVPA categories.

Among 2370 patients (55% females and mean age 73 ± 11 years), there were 464 (20%) deaths. Patients who were insufficiently active or active had a 28% (adjusted HR 0.72 (95% CI 0.54–0.97), $p=0.03$) and 47% (adjusted HR 0.53 (95% CI 0.34–0.84), $p<0.01$) lower risk of death, respectively, in the 12 months following an index COPD hospitalisation compared to inactive patients.

Any level of MVPA is associated with lower risk of all-cause mortality after a COPD hospitalisation. Routine assessment of physical activity in clinical care would identify persons at high risk for dying after COPD hospitalisation.



@ERSpublications

Any level of moderate to vigorous physical activity decreases risk of dying over 12 months after COPD hospitalisation <http://ow.ly/XZqj0>



Introduction

Chronic obstructive pulmonary disease (COPD) is characterised by acute exacerbations which result in poorer health-related quality of life, a faster decline in lung function and increased mortality [1–4]. Hospitalisations due to severe acute exacerbations account for up to 70% of the direct healthcare costs in COPD [5, 6]. Furthermore, COPD is the third most common cause of readmission among Medicare beneficiaries [7]. Re-hospitalisation and death rates are as high as 25% and 21%, respectively, at 1 year in patients who have been hospitalised for an acute exacerbations [8].

The ability to identify individuals at risk for re-hospitalisation and death after hospital admission for an acute exacerbation would allow targeting of high-risk patients for treatment and intervention. Emphasis has focused on identifying modifiable patient, provider and system factors [9]. Although studies have different lengths of follow-up time and differ as to COPD-related *versus* all-cause outcomes, they have consistently shown older age, male sex, more severe airflow obstruction, dyspnoea, oxygen use, prior hospitalisations and comorbidities to be key patient factors predicting re-hospitalisations and death [8, 10–14]. While several of these variables are already targeted by pharmacological therapy, there is a need to identify other modifiable patient factors.

Physical activity has emerged as a modifiable behaviour that is associated with COPD outcomes. The Global Initiative for Chronic Obstructive Lung Disease guidelines recommend regular physical activity for patients with stable COPD [15]. Higher levels of physical activity are associated with shorter hospital length of stay [16] and decreased risk of acute exacerbations, hospitalisations and death, independent of airflow obstruction [17–21]. In studies looking specifically at persons who had an index COPD hospitalisation, self-reported low physical activity using a research questionnaire [18] and directly measured physical activity using an accelerometer [22] were associated with an increased risk of COPD-related re-hospitalisation [18]. We similarly found that self-reported physical inactivity, assessed during routine clinical care, was associated with a 34% greater risk of 30-day all-cause readmission after an index COPD hospitalisation [23].

Although physical activity level in stable COPD is associated with mortality [24], the relationship between physical activity and risk of death in a high-risk group of patients after an index COPD hospitalisation is unknown. Therefore, our primary aim was to examine the independent relationship between physical activity and all-cause mortality in the 12 months after an index COPD hospitalisation. We hypothesise that higher physical activity at baseline predicts lower risk of all-cause mortality after a COPD hospitalisation. As a secondary aim, we also assessed the independent relationship between physical activity and a composite outcome of all-cause mortality and re-hospitalisation.

Methods

Study design

This was a retrospective cohort study of patients from an integrated healthcare system with 14 medical centres located in southern California. Subject approval was obtained from the Kaiser Permanente Southern California Institutional Review Board (Pasadena, CA, USA). Patients were included if they were hospitalised for COPD and discharged between January 1, 2011 and December 31, 2011. COPD hospitalisations were defined according to the Centres for Medicare and Medicaid Services (CMS) and National Quality Forum proposed criteria: International Classification of Diseases, Ninth Revision principal diagnosis of COPD (491.21, 491.22, 491.8, 491.9, 492.8, 493.20, 493.21, 493.22, and 496) or principal diagnosis of respiratory failure (518.81, 518.82, 518.84 and 799.1) and a secondary diagnosis of acute exacerbation of COPD (491.21, 491.22, 493.21 and 493.22) [25, 26]. We applied the following additional inclusion criteria: age \geq 40 years, prescribed a bronchodilator or corticosteroid inhaler in the 12 months prior to the index hospitalisation, alive at discharge, continuously enrolled in the health plan in the 12 months prior to the index hospitalisation, and having physical activity data. All participants were followed for 12 months post discharge or until death.

Outcomes

Primary: death

All-cause mortality in the 12 months after discharge from the index hospitalisation was the primary outcome. Mortality data were obtained from the state and national death indices which provides near complete capture of the date and cause of death. Patients who were re-hospitalised and died during or at any time after the re-hospitalisation were included in the deceased cohort.

Secondary: composite of death and re-hospitalisation

All-cause re-hospitalisation in the 12 months after discharge from the index hospitalisation and death as described above was a secondary outcome. Information on re-hospitalisations was obtained from utilisation or claims data for admissions to Kaiser Permanente medical centres or contracted hospitals, respectively.

Primary independent variable: physical activity

An exercise vital sign is assessed at all outpatient visits. The exercise vital sign has been previously shown to have construct and predictive validity [23, 27, 28]. Patients are asked two questions regarding their regular physical activity: 1) on average, how many days per week do you engage in moderate to strenuous (vigorous) exercise (like a brisk walk)?; and 2) on average, how many minutes do you engage in exercise at this level? These questions are typically asked by medical assistants. Patients' responses are entered into the electronic medical record. Response choices for number of days are categorical (0–7). Minutes are also recorded categorically: 0, 10, 20, 30, 40, 50, 60, 90, 120 and ≥ 150 . The electronic medical record software multiplies the two responses to display total minutes per week of moderate or vigorous physical activity (MVPA).

We categorised patients as inactive (0 min of MVPA per week), insufficiently active (1–149 min of MVPA per week) or active (≥ 150 min of MVPA per week) according to national physical activity recommendations [29]. We used the exercise vital sign value closest to but prior to the index hospitalisation (median (range) 30 (1–350) days prior to the index hospitalisation). An indicator for time elapsed from exercise vital sign assessment to the index hospitalisation was included in the models to account for the variable timing of the exercise vital sign assessment. We also examined three different summary values of the exercise vital sign: any level of MVPA closest to the index hospitalisation and the median/mode, and highest values of all available exercise vital sign data in the 12 months preceding the index hospitalisation since the two latter values are less influenced by the timing of the exercise vital sign assessment in our sensitivity analyses.

Covariates

We extracted administrative and clinical data in the 12 months (January 1, 2010 to December 31, 2010) prior to the index hospitalisation.

Socio-demographics

We assessed age, sex, marital status, race and insurance status. Education and household income were described at the level of the census tract since this information was not routinely collected in the electronic medical record as part of clinical care.

Comorbidities

Body mass index was obtained from the outpatient visit closest but prior to the index hospitalisation. A Charlson comorbidity score was calculated for each patient [30]. We also examined the presence of anaemia, anxiety, depression and pulmonary hypertension prior to the index hospitalisation, which have been associated with hospitalisation risk in COPD but are not included in the Charlson index [31].

Health resource utilisation

We examined the number of hospitalisations in the 12 months preceding the index hospitalisation. Length of stay, receipt of inpatient palliative care and discharge disposition were all obtained with the index hospitalisation. Pharmacy and durable medical equipment data provided information on use of inhaled bronchodilators, long-term systemic corticosteroids and supplemental oxygen in the 12 months prior to the index hospitalisation. New oxygen use after the index discharge was also assessed.

Health behaviours

Cigarette smoking status was obtained from the outpatient visit closest to the index hospitalisation. Immunisation history included influenza and pneumococcal vaccinations in the previous 1–2 years and 5 years, respectively. Any participation in pulmonary rehabilitation during the 3 years prior to the index hospitalisation was recorded.

Statistical analysis

Comparisons across MVPA categories were performed using a non-parametric Kruskal–Wallis test for continuous variables which were not normally distributed and Chi-squared tests for categorical variables. Cox proportional hazards regression models compared mortality risk across three levels of MVPA (inactive, insufficiently active and active) in the 12 months after a COPD-related hospitalisation. Covariates were examined in unadjusted models and were included in the final adjusted model if they contributed substantially to model fit or were considered clinically important. Kaplan–Meier curves were created to display survival, according to the three levels of MVPA during the 12-month follow-up. An adjusted competing risk model of cause-specific hazard was generated to determine the association between level of physical activity and cause of death (COPD-related *versus* all other causes). Cox regression was also used for the secondary composite outcome of death and re-hospitalisation.

Several sensitivity analyses were performed by: 1) including only patients who had spirometry data (n=1292) to adjust for disease severity; 2) excluding a subgroup of patients who were never-smokers (n=291) to assess

for misclassification of COPD diagnosis; and 3) using three different summary values of the exercise vital sign (any level of MVPA closest to the index hospitalisation, mode/median exercise vital sign or highest exercise vital sign in the 12 months prior to the index hospitalisation). All tests were two-sided with a p-value <0.05 considered statistically significant. Analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).

Results

Cohort selection and patient characteristics

We identified 3440 patients with COPD as their principal discharge diagnosis or who had acute respiratory failure with a secondary diagnosis of acute exacerbation of COPD from January 1, 2011 to December 31, 2011 (figure 1). The final analytical sample included 2370 patients.

A total of 1727 (73%) persons were inactive, 412 (17%) insufficiently active, and 231(10%) active. Patients had 8.4 ± 7.0 outpatient visits with exercise vital sign data in the 12 months prior to the index hospitalisation. Baseline socio-demographic and clinical characteristics stratified by level of baseline physical activity prior to the index hospitalisation are presented in table 1. Patients who were physically inactive were older, single, had lower education, were obese, were less likely to participate in rehabilitation,




FIGURE 1 Cohort selection. COPD: chronic obstructive pulmonary disease; ICD-9: International Classification of Diseases, Ninth Revision; CM: clinical modification.

TABLE 1 Characteristics of patients with index chronic obstructive pulmonary disease (COPD) hospitalisation according to level of moderate to vigorous physical activity

	Inactive 0 min·week ⁻¹	Insufficiently active 1–149 min·week ⁻¹	Active ≥150 min·week ⁻¹	Total	p-value
Subjects n	1727	412	231	2370	
Age years	73±10	71±11	71±10	73±11	<0.001
Female	963 (56)	228 (55)	117 (51)	1308 (55)	0.34
Marital status: partnered	781 (45)	204 (50)	124 (54)	1109 (47)	0.01
Education					0.002
High school or less	760 (44)	183 (44)	94 (41)	1037 (44)	
Some college or less	550 (32)	129 (31)	73 (31)	752 (32)	
College or higher	417 (24)	100 (24)	64 (28)	581 (25)	
Median household income \$					0.36
<50 000	717 (42)	161 (39)	86 (37)	964 (41)	
50 000–79 999	703 (41)	177 (43)	93 (40)	973 (41)	
80 000–99 999	189 (11)	52 (13)	35 (15)	276 (12)	
≥100 000	112 (6)	21 (5)	17 (7)	150 (6)	
Missing	6 (0)	1 (0)	0	7 (0)	
Body mass index					0.02
Underweight <18.5 kg·m ⁻²	132 (8)	25 (6)	11 (5)	168 (7)	
Normal 18.5–24.9 kg·m ⁻²	540 (31)	144 (35)	85 (37)	769 (32)	
Overweight 25–29.9 kg·m ⁻²	451 (26)	115 (28)	76 (33)	642 (27)	
Obese >30 kg·m ⁻²	604 (35)	128 (31)	59 (26)	791 (33)	
Race					0.22
White	1177 (68)	268 (65)	161 (70)	1606 (68)	
Black	248 (14)	72 (17)	29 (13)	349 (15)	
Hispanic	200 (12)	47 (11)	26 (11)	273 (12)	
Asian/Pacific Islander	63 (4)	22 (5)	13 (6)	98 (4)	
Others	12 (1)	1 (0)	1 (0)	14 (1)	
Missing	27 (2)	2 (0)	1 (0)	30 (1)	
Insurance					0.07
Commercial	355 (21)	100 (24)	58 (25)	513 (22)	
Medicaid	35 (2)	9 (2)	2 (1)	46 (2)	
Medicare	1328 (77)	296 (72)	167 (72)	1791 (76)	
Private pay	9 (1)	5 (1)	4 (2)	18 (1)	
Missing	0	2 (0)	0	2 (0)	
Smoking status					0.36
Never	200 (12)	56 (14)	35 (15)	291 (12)	
Passive	12 (1)	0 (0)	1 (0)	13 (1)	
Former	1154 (67)	276 (67)	152 (66)	1582 (67)	
Current	361 (21)	80 (19)	43 (19)	484 (20)	
Immunisation					
Influenza vaccination	1354 (78)	333 (81)	184 (80)	1871 (79)	0.54
Pneumonia vaccination	1109 (64)	279 (68)	151 (65)	1539 (65)	0.40
Pulmonary rehabilitation	103 (6)	38 (9)	21 (9)	162 (7)	0.02
FEV₁ % pred[#]	56.1±21.5	55.6±21.0	62.3±22.3	56.6±21.5	<0.01
FEV ₁ /FVC	55.5±15.8	54.4±15.9	56.2±15.2	55.3±15.7	0.65
GOLD I: ≥80% pred	112 (6)	32 (8)	30 (13)	174 (7)	0.03
GOLD II: 50%≤FEV ₁ <80% pred	432 (25)	106 (26)	63 (27)	601 (25)	
GOLD III: 30%≤FEV ₁ <50% pred	278 (16)	68 (17)	32 (14)	378 (16)	
GOLD IV: FEV ₁ <30% pred	100 (6)	30 (7)	9 (4)	139 (6)	
Missing	805 (47)	176 (43)	97 (42)	1078 (45)	
Medications					
Short-acting beta-agonist	1595 (92)	377 (92)	204 (88)	2176 (92)	0.11
Short-acting anticholinergic	1002 (58)	231 (56)	125 (54)	1358 (57)	0.45
LABA	816 (47)	189 (46)	104 (45)	1109 (47)	0.75
Long-acting anticholinergic	626 (36)	157 (38)	72 (31%)	855 (36)	0.21
ICS	1337 (77)	313 (76)	170 (74)	1820 (77)	0.39
LAMA and ICS [¶]	546 (32)	134 (33)	66 (29)	746 (31)	0.57
LABA and ICS [¶]	808 (47)	188 (46)	102 (44)	1098 (46)	0.72
Long-term systemic corticosteroids	235 (14)	55 (13)	19 (8)	309 (13)	0.07
Oxygen use prior to index hospitalisation	315 (18)	70 (17)	24 (10)	409 (17)	0.01
New oxygen use post-index hospitalisation	184 (11)	52 (13)	31 (13)	267 (11)	0.29

Continued

TABLE 1 Continued

	Inactive 0 min-week ⁻¹	Insufficiently active 1–149 min-week ⁻¹	Active ≥150 min-week ⁻¹	Total	p-value
Comorbidities					
Anaemia present at hospitalisation	280 (16)	71 (17)	29 (13)	380 (16)	0.28
Heart failure	664 (38)	134 (33)	48 (21)	846 (36)	<0.001
Pulmonary hypertension	243 (14)	49 (12)	18 (8)	310 (13)	0.02
Diabetes	590 (34)	130 (32)	60 (26)	780 (33)	0.04
Depression	359 (21)	82 (20)	35 (15)	476 (20)	0.13
Anxiety	110 (6)	34 (8)	12 (5)	156 (7)	0.26
Solid tumour without metastasis	297 (17)	68 (17)	41 (18)	406 (17)	0.91
Metastatic cancer	43 (2)	10 (2)	2 (1)	55 (2)	0.30
Charlson comorbidity index	4.0±2.6	3.7±2.6	3.1±2.4	3.9±2.6	<0.001
0–1	332 (19)	91 (22)	63 (27)	486 (21)	<0.01
2	280 (16)	71 (17)	49 (21)	400 (17)	
≥3	1115 (65)	250 (61)	119 (52)	1484 (63)	
Hospitalisation in prior year					
COPD-related hospitalisation	487 (28)	110 (27)	44 (19)	641 (27)	<0.01
	2.0±1.8	2.1±1.9	1.8±1.8	2.0±1.8	
Non-COPD-related hospitalisation	380 (22)	88 (21)	51 (22)	519 (22)	0.05
	2.4±2.2	2.3±2.2	2.0±1.5	2.3±2.2	
Length of stay for index hospitalisation days	4.9±4.1	4.3±3.0	4.2±2.9	4.7±3.9	0.04
1–2	389 (23)	109 (26)	69 (30)	567 (24)	
3	386 (22)	108 (26)	55 (24)	549 (23)	
4–6	636 (37)	135 (33)	78 (34)	849 (36)	
7–13	256 (15)	51 (12)	25 (11)	332 (14)	
14–59	60 (3)	9 (2)	4 (2)	73 (3)	
Discharge disposition for index hospitalisation					
Home	1508 (87)	386 (94)	221 (96)	2115 (89)	0.001
Post-acute (skilled nursing)	125 (7)	16 (4)	6 (3)	147 (6)	
Hospice	56 (3)	5 (1)	1 (0)	62 (3)	
Hospital	6 (0)	0 (0)	0 (0)	6 (0)	
Other	11 (1)	1 (0)	1 (0)	13 (1)	
Missing	21 (1)	4 (1)	2 (1)	27 (1)	
Palliative care consultation during index hospitalisation	106 (6)	15 (4)	4 (2)	125 (5)	0.005

Data are presented as mean±SD or n (%), unless otherwise stated. FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LABA: long-acting β-agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid. #: n=1292; †: numbers might not add up as patients are included in the count if they are on an ICS and LABA or LAMA.

used supplemental oxygen, had worse airflow obstruction and more comorbidities, and were more likely to have a COPD hospitalisation in the previous year compared to active patients (p<0.05).

There were 464 (20%) deaths and 1028 (43%) re-hospitalisations that did not result in death over 12 months (table 2). A majority of the deaths (74%) were preceded by a re-hospitalisation and approximately half of the deaths occurred within 60 days of the re-hospitalisation. COPD was the primary cause of death (46%), followed by malignancies (21%) and cardiovascular disease (15%).

Primary outcome

Unadjusted analyses of the relationship between MVPA with all-cause mortality

Patients meeting the national recommendation of engaging in at least 150 min-week⁻¹ of MVPA had a 65% lower risk of death in the 12 months following an index COPD hospitalisation compared to inactive patients (HR 0.35 (95% CI 0.22–0.55), p<0.001) (table 3). Those who were insufficiently active (1–149 min-week⁻¹ of MVPA) had a 46% lower risk of dying compared to inactive patients (HR 0.54 (95% CI 0.40–0.72), p<0.001).

Multivariate adjusted analyses of the relationship between MVPA and all-cause mortality

After adjustments for all key covariates (socio-demographics, medication use, previous hospitalisations, comorbidities, length of stay, discharge disposition and a palliative care consultation with the index

TABLE 2 Deaths and re-hospitalisations in the 12 months following index chronic obstructive pulmonary disease hospitalisation according to level of moderate to vigorous physical activity

	Inactive 0 min·week ⁻¹	Insufficiently inactive 1–149 min·week ⁻¹	Active >150 min·week ⁻¹	Total
Subjects n	1727	412	231	2370
Deaths [#]	391 [23]	53 [13]	20 [9]	464 [20]
No re-hospitalisation	104 [6]	15 [4]	3 [1]	122 [5]
At, during or after re-hospitalisation	287 [17]	38 [9]	17 [7]	342 [14]
Re-hospitalisations only	740 [43]	187 [45]	101 [44]	1028 [43]

Data are presented as n (%), unless otherwise stated. #: 342 (74%) of all deaths were preceded by a re-hospitalisation.

hospitalisation, and previous exposure to pulmonary rehabilitation), patients who reported being insufficiently active or active had a significantly lower risk of death compared to inactive patients (table 3 and figure 2). Specifically, active patients had a 47% lower risk of death in the 12 months following an index COPD hospitalisation compared to inactive patients (HR 0.53 (95% CI 0.34–0.84), $p < 0.01$). Those who were insufficiently active had a 28% lower risk of dying compared to inactive patients (HR 0.72 (95% CI 0.54–0.97), $p = 0.03$). Other significant predictors of mortality in the adjusted model included older age, being underweight, being a current smoker, taking chronic corticosteroids, Charlson index score of ≥ 3 , pulmonary hypertension, longer length of stay, inpatient palliative care and discharge to hospice. Being female, overweight or obese and previous participation in rehabilitation remained protective.

Multivariate adjusted competing risk-cause of death analysis

There was a significant relationship between level of MVPA and COPD-related cause of death ($p = 0.02$) after adjustment for a similar set of covariates as the main model above. Specifically, patients who were inactive had almost a four-fold higher risk of dying of COPD-related causes compared to active patients (HR 3.8 (95% CI 1.41–10.42)). Patients who were insufficiently active had a three times higher risk of dying due to COPD compared to active patients (HR 3.0 (95% CI 1.02–8.64)).

Secondary outcome: composite of death and re-hospitalisation

MVPA was significantly associated with death and re-hospitalisation in the 12 months following an index COPD hospitalisation in both unadjusted and adjusted models, though the effects were smaller compared to the main model with death as the only primary outcome (table 4). Additional factors in the multivariate model that were significantly associated with increased risk of death or re-hospitalisation included being underweight, using systemic corticosteroids, previous hospitalisation, Charlson index score of ≥ 2 , pulmonary hypertension, longer length of stay during the index hospitalisation and being discharged to a hospice.

Sensitivity analyses

In the subset of patients with spirometry data, the model that adjusted for forced expiratory volume in 1 s % pred showed that the magnitude of the risk of death was similar to the main model for the active patients (HR 0.53 (95% CI 0.28–1.01), $p = 0.06$) and attenuated for the insufficiently active patients (HR 0.88 (95% CI 0.60–1.28), $p = 0.50$), compared to inactive patients (table 5). In this sensitivity analysis we found that forced expiratory volume in 1 s % pred was a marginally significant predictor of death ($p = 0.06$). When we excluded a subgroup of patients who were never-smokers we found that the risk of death was similar to the main model (active: HR 0.57 (95% CI 0.35–0.90), $p = 0.02$; insufficiently active: HR 0.71 (95% CI 0.52–0.97), $p = 0.03$). Using three different summary values of exercise vital sign, we found risks for death similar to the main model: any MVPA versus no MVPA (HR 0.66 (95% CI 0.51–0.85), $p < 0.001$); mode/median (active: HR 0.62 (95% CI 0.37–1.03), $p = 0.07$; insufficiently active: HR 0.61 (95% CI 0.43–0.88), $p < 0.01$) and highest (active: HR 0.59 (95% CI 0.47–0.76), $p < 0.001$; insufficiently active: HR 0.69 (95% CI 0.55–0.85), $p = 0.001$).

Discussion


Patients with COPD-related hospitalisation who engaged in any level of MVPA prior to the index hospitalisation had a 28–47% lower risk of dying over the subsequent 12 months compared to patients who performed no MVPA. Higher levels of MVPA were significantly associated with a lower risk of dying from COPD but not with other causes of death, with any amount of MVPA being beneficial. We have shown that patient self-reporting physical activity using two simple questions, which can be easily assessed in routine care, has predictive value. Our findings demonstrate the importance of routinely assessing

TABLE 3 Unadjusted and adjusted Cox proportional hazard regression models predicting mortality 12 months after index chronic obstructive pulmonary disease (COPD) hospitalisation in 2370 patients with COPD

Factor	Unadjusted models		Adjusted model	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Baseline MVPA activity (closest to index hospitalisation)				
0 min·week ⁻¹	1.0		1.0	
1–149 min·week ⁻¹	0.54 (0.40–0.72)	<0.001	0.72 (0.54–0.97)	0.03
≥150 mins·week ⁻¹	0.35 (0.22–0.55)	<0.001	0.53 (0.34–0.84)	<0.01
Physical activity assessment time				
Increase of 1 day prior to index hospitalisation	1.00 (0.99–1.00)	0.89	1.00 (0.99–1.00)	0.91
Age				
Increase of 1 year	1.05 (1.04–1.06)	<0.001	1.04 (1.02–1.05)	<0.001
Sex				
Female <i>versus</i> male	0.82 (0.68–0.98)	0.03	0.76 (0.62–0.93)	<0.01
Marital status				
Single <i>versus</i> partnered	1.21 (0.10–1.46)	0.05	1.04 (0.85–1.27)	0.73
BMI				
Normal 18.5–24.9 kg·m ⁻²	1.0		1.0	
Underweight <18.5 kg·m ⁻²	2.14 (1.64–2.81)	<0.001	2.40 (1.82–3.16)	<0.001
Overweight 25–29.9 kg·m ⁻²	0.64 (0.50–0.81)	<0.001	0.70 (0.54–0.89)	<0.01
Obese >30 kg·m ⁻²	0.49 (0.39–0.63)	<0.001	0.64 (0.49–0.83)	<0.001
Race/ethnicity				
Non-White <i>versus</i> White	0.84 (0.69–1.03)	0.10	0.95 (0.77–1.17)	0.61
Smoking status				
Never/passive	1.0		1.0	
Former	1.53 (1.11–2.09)	0.01	1.34 (0.97–1.85)	0.07
Current	1.24 (0.86–1.78)	0.25	1.62 (1.10–2.38)	0.01
Medications				
LABA/ICS or LAMA/ICS <i>versus</i> none	0.90 (0.75–1.08)	0.27	0.87 (0.72–1.06)	0.16
Systemic corticosteroids <i>versus</i> none	1.71 (1.36–2.15)	<0.001	1.40 (1.10–1.78)	<0.01
Any oxygen use <i>versus</i> none	1.48 (1.22–1.79)	<0.001	1.16 (0.95–1.41)	0.15
Hospitalisations				
Any previous hospitalisations <i>versus</i> none	1.45 (1.21–1.74)	<0.001	1.11 (0.91–1.36)	0.31
Comorbidities				
Charlson index score				
0–1	1.0		1.0	
2	1.31 (0.90–1.91)	0.16	1.21 (0.82–1.78)	0.34
≥ 3	2.43 (1.82–3.25)	<0.001	1.75 (1.28–2.39)	<0.001
Pulmonary hypertension	2.08 (1.67–2.59)	<0.001	1.69 (1.34–2.12)	<0.001
Depression	1.09 (0.88–.36)	0.44	1.05 (0.84–1.33)	0.65
Pulmonary rehabilitation				
Yes <i>versus</i> no	0.33 (0.19–0.58)	<0.001	0.47 (0.26–0.85)	0.01
Palliative care consultation				
Yes <i>versus</i> no	4.40 (3.41–5.69)	<0.001	1.70 (1.26–2.29)	<0.001
Length of stay days				
1–2	1.0		1.0	
3	1.20 (0.88–1.63)	0.25	1.27 (0.93–1.74)	0.13
4–6	1.69 (1.29–2.20)	<0.001	1.60 (1.21–2.09)	<0.001
7–13	2.20 (1.62–2.98)	<0.001	1.87 (1.35–2.57)	<0.001
14–59	3.20 (2.05–4.99)	<0.001	2.48 (1.51–4.08)	<0.001
Disposition				
Home	1.0		1.0	
Hospice	11.25 (8.39–15.1)	<0.001	5.23 (3.74–7.34)	<0.001
Post-acute/hospital	2.64 (1.99–3.51)	<0.001	1.37 (0.99–1.90)	0.06
Other/missing	2.02 (1.13–3.59)	0.02	1.51 (0.84–2.71)	0.17

The adjusted model included all variables listed in this table. Bold indicates statistical significance. MVPA: moderate to vigorous physical activity; BMI: body mass index; LABA: long-acting β -agonist; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic antagonist.

FIGURE 2 Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and vigorous physical activity (Log rank test, $p < 0.0001$).



physical activity in clinical care to identify high-risk patients, as well as the need to conduct prospective controlled studies to determine if interventions to increase MVPA improve survival in patients who have been hospitalised for a COPD exacerbation.

Although physical activity has been shown to be a predictor of death in stable outpatient cohorts [17, 18, 20, 24], this is the first study to our knowledge demonstrating low physical activity to be an independent predictor of death in a high-risk cohort hospitalised for an acute exacerbation. Our results also provide an estimate of the magnitude of the risk for death in inactive persons with COPD after a hospitalisation. These findings are pragmatic in informing specific clinical recommendations to patients and have high clinical relevance.

It is important to note that nearly 75% of the deaths were preceded by a hospitalisation for COPD or other causes. When we examined death and re-hospitalisation as a composite outcome, we found that MVPA remained a strong independent predictor. While our findings suggest that physical activity level is another useful predictor of mortality, engagement in any level of MVPA and thus maintenance of a physically active lifestyle in this population could potentially buffer the physical and emotional stresses of repeated hospitalisations due to COPD or other causes. The physiological processes underlying the relationship between physical activity and COPD outcomes are complex and only partially understood. However, it has been hypothesised that physical inactivity leads to cellular and molecular dysregulation [32] *via* increased inflammatory processes [33–36], which directly contributes to the development and progression of multiple comorbidities [37, 38]. A recent longitudinal study that monitored physical activity for 3 years in stable patients with COPD found that, independent of disease severity, patients who were persistently inactive had greater declines in functional capacity and fat-free mass compared to those who engaged in some level of physical activity [39].

We also identified other lifestyle factors such as active cigarette smoking, no participation in pulmonary rehabilitation and poor nutritional status (represented by low body mass index) as independent predictors of death. Our study emphasises the need for continued multidisciplinary interventions to improve outcomes by promoting long-term behaviour change. Other significant independent predictors of death, such as older age, male sex, use of systemic corticosteroids, history of prior hospitalisations [8, 40], greater numbers of comorbidities [8, 10], pulmonary hypertension [8] and longer length of stay [8] are consistent with previous studies.

The strengths of our study include a relatively well-characterised, large, contemporary, racially diverse and sex balanced sample, and the use of physical activity data that are routinely captured during clinical practice, complete capture of utilisation and claims data, and estimates of the effects of physical activity on death that remain robust to sensitivity analyses.

There are several limitations to this study. Since physical activity was self-reported during routine outpatient encounters, it is possible that patients may have been experiencing an exacerbation when the exercise vital sign data were collected or that, for patients who were later hospitalised, the closest exercise vital sign data already reflected the diminished physical activity associated with their current illness. However, our risk estimates remained robust despite adjustments for the time between the index hospitalisation and exercise vital sign assessment and using different summary values of exercise vital sign that are less affected by timing of the assessment. In addition, we recognise that the classification of MVPA according to the

TABLE 4 Unadjusted and adjusted Cox proportional hazard regression models predicting the composite outcome of mortality and re-hospitalisations 12 months after index chronic obstructive pulmonary disease (COPD) hospitalisation in 2370 patients with COPD

Factor	Unadjusted models		Adjusted model	
	HR (95% CI)	p-value	(HR 95% CI)	p-value
Baseline MVPA (closest to index hospitalisation)				
0 min·week ⁻¹	1.0		1.0	
1–149 min·week ⁻¹	0.80 (0.69–0.92)	<0.01	0.85 (0.73–0.97)	0.02
≥150 min·week ⁻¹	0.67 (0.55–0.81)	<0.001	0.75 (0.62–0.91)	<0.01
Physical activity assessment time				
Increase of 1 day prior to index hospitalisation	1.0 (0.99–1.00)	<0.01	1.0 (0.99–1.00)	0.03
Age				
Increase of 1 year	1.01 (1.01–1.02)	<0.001	1.00 (1.00–1.01)	0.28
Sex				
Female <i>versus</i> male	0.96 (0.86–1.06)	0.39	0.95 (0.85–1.06)	0.38
Marital status				
Single <i>versus</i> partnered	1.10 (0.99–1.22)	0.07	1.06 (0.95–1.18)	0.32
BMI				
Normal 18.5–24.9 kg·m ⁻²	1.0		1.0	
Underweight <18.5 kg·m ⁻²	1.20 (0.98–1.47)	0.07	1.27 (1.03–1.55)	0.02
Overweight 25–29.9 kg·m ⁻²	1.01 (0.88–1.15)	0.94	1.01 (0.88–1.15)	0.91
Obese >30 kg·m ⁻²	0.88 (0.78–1.00)	0.05	0.86 (0.75–0.99)	0.04
Race/ethnicity				
Non-White <i>versus</i> White	1.04 (0.93–1.16)	0.50	1.05 (0.94–1.18)	0.38
Smoking status				
Never/passive	1.0		1.0	
Former	1.12 (0.96–1.31)	0.15	1.05 (0.89–1.23)	0.55
Current	0.84 (0.70–1.01)	0.07	1.00 (0.81–1.22)	0.96
Medications				
LABA/ICS or LAMA/ICS <i>versus</i> none	1.20 (1.08–1.33)	<0.001	1.10 (0.99–1.22)	0.09
Systemic corticosteroids <i>versus</i> none	1.54 (1.34–1.76)	<0.001	1.20 (1.04–1.38)	<0.01
Any oxygen use <i>versus</i> none	1.13 (1.01–1.26)	0.04	1.02 (0.91–1.14)	0.80
Hospitalisations				
Any previous hospitalisations <i>versus</i> none	1.72 (1.55–1.90)	<0.001	1.45 (1.30–1.63)	<0.001
Comorbidities				
Charlson index				
0–1	1.0		1.0	
2	1.34 (1.11–1.60)	<0.01	1.21 (1.01–1.46)	0.04
≥3	1.85 (1.61–2.14)	<0.001	1.50 (1.28–1.75)	<0.001
Pulmonary hypertension	1.52 (1.32–1.75)	<0.001	1.23 (1.07–1.42)	<0.001
Depression	1.13 (1.00–1.28)	0.05	1.02 (0.89–1.15)	0.82
Pulmonary rehabilitation				
Yes <i>versus</i> none	0.99 (0.81–1.20)	0.89	1.00 (0.82–1.23)	0.97
Palliative care consultation				
Yes <i>versus</i> no	1.80 (1.47–2.20)	<0.001	1.19 (0.95–1.49)	0.14
Length of stay days				
1–2	1.0		1.0	
3	1.03 (0.88–1.20)	0.71	1.04 (0.89–1.22)	0.59
4–6	1.31 (1.15–1.51)	<0.001	1.24 (1.08–1.43)	<0.001
7–13	1.47 (1.24–1.74)	<0.001	1.33 (1.11–1.58)	<0.001
14–59	2.07 (1.56–2.75)	<0.001	1.71 (1.26–2.32)	<0.001
Disposition				
Home	1.0		1.0	
Hospice	2.56 (1.96–3.35)	<0.001	1.74 (1.30–2.33)	<0.001
Post-acute/hospital	1.41 (1.16–1.72)	<0.001	1.14 (0.92–1.41)	0.22
Other/missing	1.06 (0.71–1.59)	0.78	1.03 (0.69–1.56)	0.87

The adjusted model included all variables listed in this table. Bold indicates statistical significance. MVPA: moderate to vigorous physical activity; BMI: body mass index; LABA: long-acting β -agonist; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic antagonist.

TABLE 5 Sensitivity analyses for the primary outcome of mortality

Factor	Subjects n	Adjusted model HR (95% CI)	p-value
Baseline MVPA (closest to index hospitalisation)			
Patients with spirometry ^{#,¶}	1292		
0 min·week ⁻¹		1.0	
1–149 min·week ⁻¹		0.88 [0.60–1.28]	0.50
≥150 min·week ⁻¹		0.53 [0.28–1.01]	0.06
Patients with smoking history [#]	2066		
0 min·week ⁻¹		1.0	
1–149 min·week ⁻¹		0.71 [0.52–0.97]	0.03
≥150 min·week ⁻¹		0.57 [0.35–0.90]	0.02
Any MVPA[#] (closest to index hospitalisation)			
0 min·week ⁻¹	2370	1.0	
≥1 min·week ⁻¹		0.66 [0.51–0.85]	<0.001
Median/mode MVPA⁺			
0 min·week ⁻¹	2370	1.0	
1–149 min·week ⁻¹		0.61 [0.43–0.88]	<0.01
≥150 min·week ⁻¹		0.62 [0.37–1.03]	0.07
Highest MVPA[§]			
0 min·week ⁻¹	2370	1.0	
1–149 min·week ⁻¹		0.69 [0.55–0.85]	<0.001
≥150 min·week ⁻¹		0.59 [0.47–0.76]	<0.001

Cox regression models adjusted for age, marital status, race/ethnicity, body mass index, smoking status, disease severity (medications, oxygen use, Charlson comorbidity index, pulmonary hypertension, depression, any hospitalisation in previous 12 months), ever attended pulmonary rehabilitation in the 3 years prior to the index hospitalisation, palliative care consultation during the index hospitalisation, length of stay, discharge disposition and duration of time from assessment of physical activity to index hospitalisation. MVPA: moderate to vigorous physical activity. [#]: included on indicated models; [¶]: forced expiratory volume in 1s % predicted was included in the adjusted model and was not a significant predictor of death; ^{*}: based on all physical activity readings over 12 months prior to index hospitalisation; [§]: highest physical activity reading over 12 months prior to index hospitalisation.

exercise vital sign questions for this clinical population is subjective and only captures patients' actual functional performance not their capacity, which would normally be assessed with objective cardiopulmonary exercise testing. Moreover, patients' level of MVPA is probably dependent on their capacity. Lung function was not assessed in all patients, but our inclusion criteria and sensitivity analysis argue against any significant misclassification. We adhered to the CMS definition of hospitalisation for COPD exacerbations in order to be as generalisable as possible, to allow comparison with other studies and to most accurately reflect real-world settings. Because of the retrospective, observational design that relied on the availability of existing data, we may not have accurately captured all variables of interest, e.g. symptom severity and exercise capacity, and we are not able to make strong inferences about causation.

Conclusions

Using a routine simple exercise vital sign, patients who report engagement in any level of MVPA are at lower risk of dying in the 12 months following an index COPD hospitalisation, compared to those who are physically inactive. Assessment of physical activity should be routinely performed in clinical care to identify high-risk patients.

References

- 1 Albert RK, Connett J, Bailey WC, *et al.* Azithromycin for prevention of exacerbations of COPD. *N Engl J Med* 2011; 365: 689–698.
- 2 Hurst JR, Vestbo J, Anzueto A, *et al.* Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010; 363: 1128–1138.
- 3 Connors AF Jr, Dawson NV, Thomas C, *et al.* Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am J Respir Crit Care Med* 1996; 154: 959–967.
- 4 Seemungal TA, Donaldson GC, Paul EA, *et al.* Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998; 157: 1418–1422.
- 5 Patil SP, Krishnan JA, Lechtzin N, *et al.* In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. *Arch Intern Med* 2003; 163: 1180–1186.

- 6 Strassels SA, Smith DH, Sullivan SD, *et al.* The costs of treating COPD in the United States. *Chest* 2001; 119: 344–352.
- 7 Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *N Engl J Med* 2009; 360: 1418–1428.
- 8 McGhan R, Radcliff T, Fish R, *et al.* Predictors of rehospitalization and death after a severe exacerbation of COPD. *Chest* 2007; 132: 1748–1755.
- 9 Sharif R, Parekh TM, Pierson KS, *et al.* Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2014; 11: 685–694.
- 10 Almagro P, Cabrera FJ, Diez J, *et al.* Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. *Chest* 2012; 142: 1126–1133.
- 11 Almagro P, Calbo E, Ochoa de Echaguen A, *et al.* Mortality after hospitalization for COPD. *Chest* 2002; 121: 1441–1448.
- 12 Kessler R, Faller M, Fourgaut G, *et al.* Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999; 159: 158–164.
- 13 Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. *Chest* 2003; 124: 459–467.
- 14 Garcia-Aymerich J, Farrero E, Felez MA, *et al.* Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. *Thorax* 2003; 58: 100–105.
- 15 Vestbo J, Hurd SS, Agusti AG, *et al.* Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. *Am J Respir Crit Care Med* 2013; 187: 347–365.
- 16 Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, *et al.* Predictors of hospital length of stay in patients with exacerbations of COPD: a cohort study. *J Gen Intern Med* 2015; 30: 824–831.
- 17 Vaes AW, Garcia-Aymerich J, Marott JL, *et al.* Changes in physical activity and all-cause mortality in COPD. *Eur Respir J* 2014; 44: 1199–1209.
- 18 Garcia-Aymerich J, Lange P, Benet M, *et al.* Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. *Thorax* 2006; 61: 772–778.
- 19 Moy ML, Teylan M, Weston NA, *et al.* Daily step count predicts acute exacerbations in a US cohort with COPD. *PLoS One* 2013; 8: e60400.
- 20 Waschki B, Kirsten A, Holz O, *et al.* Physical activity is the strongest predictor of all-cause mortality in patients with chronic obstructive pulmonary disease: a prospective cohort study. *Chest* 2011; 140: 331–342.
- 21 Moy ML, Teylan M, Danilack VA, *et al.* An index of daily step count and systemic inflammation predicts clinical outcomes in chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2014; 11: 149–157.
- 22 Chawla H, Bulathsinghala C, Tejada JP, *et al.* Physical activity as a predictor of thirty-day hospital readmission after a discharge for a clinical exacerbation of chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2014; 11: 1203–1209.
- 23 Nguyen HQ, Chu L, Liu IL, *et al.* Associations between physical activity and 30-day readmission risk in chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2014; 11: 695–705.
- 24 Gimeno-Santos E, Frei A, Steurer-Stey C, *et al.* Determinants and outcomes of physical activity in patients with COPD: a systematic review. *Thorax* 2014; 69: 731–739.
- 25 Stein BD, Bautista A, Schumock GT, *et al.* The validity of International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for identifying patients hospitalized for COPD exacerbations. *Chest* 2012; 141: 87–93.
- 26 National Quality Forum. NQF #1891 Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization. Measure submission and evaluation worksheet 5.0. Washington, National Quality Forum, 2012.
- 27 Coleman KJ, Ngor E, Reynolds K, *et al.* Initial validation of an exercise “vital sign” in electronic medical records. *Med Sci Sports Exerc* 2012; 44: 2071–2076.
- 28 Grant RW, Schmittiel JA, Neugebauer RS, *et al.* Exercise as a vital sign: a quasi-experimental analysis of a health system intervention to collect patient-reported exercise levels. *J Gen Intern Med* 2014; 29: 341–348.
- 29 Prevalence of self-reported physically active adults – United States, 2007. *MMWR Morb Mortal Wkly Rep* 2008; 57: 1297–1300.
- 30 Charlson ME, Pompei P, Ales KL, *et al.* A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; 40: 373–383.
- 31 Roberts CM, Stone RA, Lowe D, *et al.* Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. *COPD* 2011; 8: 354–361.
- 32 Thompson PD, Buchner D, Pina IL, *et al.* Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. *Circulation* 2003; 107: 542–550.
- 33 Moy ML, Teylan M, Weston NA, *et al.* Daily step count is associated with plasma C-reactive protein and IL-6 in a US Cohort with COPD. *Chest* 2014; 145: 3109–3116.
- 34 Troosters T, van der Molen T, Polkey M, *et al.* Improving physical activity in COPD: towards a new paradigm. *Respir Res* 2013; 14: 115.
- 35 Broekhuizen R, Wouters EF, Creutzberg EC, *et al.* Raised CRP levels mark metabolic and functional impairment in advanced COPD. *Thorax* 2006; 61: 17–22.
- 36 Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). *Proc Am Thorac Soc* 2007; 4: 522–525.
- 37 Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. *Epidemiology* 2002; 13: 561–568.
- 38 Watz H, Waschki B, Kirsten A, *et al.* The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. *Chest* 2009; 136: 1039–1046.
- 39 Waschki B, Kirsten AM, Holz O, *et al.* Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 192: 295–306.
- 40 Garcia-Aymerich J, Monso E, Marrades RM, *et al.* Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. *Am J Respir Crit Care Med* 2001; 164: 1002–1007.